Remus PharmaceuticalsNSE:REMUS -4.49%54 OCF Yield % is 1.94 as of Jul. 02, 2026, which is 166% above its 10-year median of 0.73. GuruFocus rates NSE:REMUS with a GF Score™ of 54/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 64.1% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Remus Pharmaceuticals OCF Yield % Related Terms
Remus Pharmaceuticals OCF Yield % Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: OCF Yield % Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals OCF Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a OCF Yield % of 1.94 as of Jul. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Remus Pharmaceuticals and its competitors. This is 166% above median its historical median of 0.73. Over the past decade, Remus Pharmaceuticals' OCF Yield % has ranged from 0.09 to 3.05. According to the industry distribution chart, Remus Pharmaceuticals ranks #75 out of 117 companies in the Medical Distribution industry, placing it in the top 64.1%.
Is Remus Pharmaceuticals' OCF Yield % too high?
Remus Pharmaceuticals' current OCF Yield % of 1.94 is 166% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 3.05. The Medical Distribution industry median OCF Yield % is 6.00. Remus Pharmaceuticals' value of 1.94 is 67.7% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #75 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' OCF Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #75 out of 117 companies for OCF Yield %. This places Remus Pharmaceuticals in the lower half of its industry. The industry median OCF Yield % is 6.00. Remus Pharmaceuticals' value of 1.94 is 67.7% below this benchmark. Historically, Remus Pharmaceuticals' own OCF Yield % has ranged from 0.09 to 3.05 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 6.00, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Distribution company?
The median OCF Yield % among Medical Distribution companies is 6.00, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current OCF Yield % of 1.94 is 67.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median OCF Yield % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current OCF Yield % is 1.94, which is 166% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹744.30 — trading 64.1% below its estimated fair value. The current OCF Yield % is 1.94, which is 166% above median its 10-year median of 0.73 and 67.7% below the Medical Distribution industry median of 6.00. Remus Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current OCF Yield % is 1.94 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹744.30 is trading 64.1% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
OCF Yield %: 1.94 (166% above median its 10-year median of 0.73)
GF Value™: ₹2,071.36 vs. price of ₹744.30 (64.1% below fair value)
Industry Position: 67.7% below the Medical Distribution median (#75 of 117)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
54GF Score
Get the complete analysis for NSE:REMUS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
